HKSE - Delayed Quote HKD

Kintor Pharmaceutical Limited (9939.HK)

1.100

-0.010

(-0.90%)

At close: April 17 at 4:08:07 PM GMT+8

Asian Penny Stocks: 3 Picks With Market Caps Under US$300M

As global markets navigate a landscape of economic uncertainty and mixed data, investor interest in smaller-cap opportunities continues to grow. Though the term 'penny stock' might sound like a relic of past trading days, the opportunity it points to is still relevant. These typically smaller or newer companies can offer significant growth potential when backed by strong financials and solid fundamentals.

Simply Wall St. 25 days ago

KNTPF

U10.SI
3 Promising Penny Stocks With Market Caps Over US$50M

Global markets have been experiencing a notable upswing, with U.S. stock indexes nearing record highs and growth stocks outpacing their value counterparts. In this context, penny stocks—though often seen as a niche investment—can still offer intriguing opportunities for those interested in smaller or newer companies. By focusing on penny stocks with solid financial health, investors might find potential for growth and stability in an ever-evolving market landscape.

Simply Wall St. last month

KNTPF

UPP.AE
Grown Up Group Investment Holdings Among 3 Intriguing Penny Stocks

As global markets respond to political shifts and economic policies, investors are witnessing a rally in major U.S. indices, with small-cap stocks showing significant movement. In this context, penny stocks—though an outdated term—remain an intriguing area for investment due to their potential for growth in smaller or newer companies. When these stocks are supported by strong financial health, they can offer unique opportunities that larger firms might overlook.

Simply Wall St. 5 months ago

1842.HK

KNTPF

S41.SI
GT20029 China Phase II Trial For AGA Reached Primary Endpoint

Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the China phase II clinical trial (the "Phase II Clinical Trial") of its in-house developed first-in-class androgen receptor ("AR") proteolysis targeting chimera ("PROTAC") compound GT20029 tincture for the treatment of male androgenetic alopecia ("AGA") has reached the primary endpoint, with statistically significan

PR Newswire 11 months ago

KNTPF

Performance Overview

Return	9939.HK	HANG SENG INDEX (^HSI)
YTD	+13.40%	+6.66%
1-Year	+34.15%	+31.65%
3-Year	-96.00%	-0.57%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Kintor Pharmaceutical Limited (9939.HK)

Asian Penny Stocks: 3 Picks With Market Caps Under US$300M

3 Promising Penny Stocks With Market Caps Over US$50M

Grown Up Group Investment Holdings Among 3 Intriguing Penny Stocks

GT20029 China Phase II Trial For AGA Reached Primary Endpoint

Performance Overview